Analyst Clara Dong of Jefferies maintained a Buy rating on BeOne Medicines, with a price target of $420.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clara Dong has given her Buy rating due to a combination of factors including BeOne Medicines’ robust global vision and impressive financial performance. The company has shown rapid revenue growth in the US and EU, with its flagship product Brukinsa achieving over $1 billion in revenue, making it the leading BTKi in the global market. Additionally, the company’s strategic redomiciliation to Switzerland and its strong performance in China and the EU further bolster its financial outlook.
BeOne Medicines’ commitment to rapid and high-quality clinical development is another key reason for the Buy rating. The company is advancing its solid tumor pipeline with significant speed and efficiency, supported by its vertically integrated model and proprietary CRO. This approach allows for streamlined trial processes and priority site relationships. The company’s CLL franchise, which includes Brukinsa, BCL2 inhibitor Sonrotoclax, and a BTK degrader, is positioned to capture a significant share of the CLL market, with promising data and upcoming trials that could further enhance its market position.
According to TipRanks, Dong is a 2-star analyst with an average return of 0.8% and a 50.00% success rate. Dong covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Heron Therapeutics, and Aldeyra Therapeutics.
In another report released on November 10, CMB International Securities also maintained a Buy rating on the stock with a $392.43 price target.